New pill targets Hard-to-Treat cancers with TP53 mutation
Disease control
Recruiting now
This study tests an experimental oral drug called NTS071 in adults with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The trial has two phases: first, to check safety and find the right dose, and second, to see if the drug shrinks tumors. Ab…
Phase: PHASE1, PHASE2 • Sponsor: Nutshell Therapeutics (Shanghai) Co., LTD. • Aim: Disease control
Last updated Jun 23, 2026 23:31 UTC